Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced a key leadership transition, with Daniel Apel appointed as the new Chief Financial Officer, effective May 13, 2025. He will succeed Ken Myszkowski, who is retiring after 16 years with the company. Myszkowski will remain as an employee adviser to ensure a smooth transition.
Apel joins Arrowhead from Walgreens Boots Alliance, where he served as Global Head of Financial Planning and Analysis (2019-2024). His extensive experience includes nearly 20 years at Bayer, where he held positions as CFO of Bayer U.S. (2016-2019) and CFO of Bayer Canada. The transition comes as Arrowhead prepares for its planned launch of plozasiran this year, pending regulatory approval, marking the company's shift from development to commercial stage.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) ha annunciato un importante cambio ai vertici, con la nomina di Daniel Apel a nuovo Chief Financial Officer, a partire dal 13 maggio 2025. Succederà a Ken Myszkowski, che andrà in pensione dopo 16 anni in azienda. Myszkowski resterà come consulente interno per garantire un passaggio di consegne senza intoppi.
Apel arriva in Arrowhead da Walgreens Boots Alliance, dove ha ricoperto il ruolo di Global Head of Financial Planning and Analysis (2019-2024). La sua vasta esperienza comprende quasi 20 anni in Bayer, dove ha ricoperto le cariche di CFO di Bayer U.S. (2016-2019) e CFO di Bayer Canada. Questo cambio avviene mentre Arrowhead si prepara al lancio pianificato di plozasiran entro quest’anno, soggetto all’approvazione regolatoria, segnando il passaggio dell’azienda dalla fase di sviluppo a quella commerciale.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) anunció una importante transición en su liderazgo, con la designación de Daniel Apel como nuevo Director Financiero, con efecto a partir del 13 de mayo de 2025. Reemplazará a Ken Myszkowski, quien se retira tras 16 años en la empresa. Myszkowski permanecerá como asesor interno para asegurar una transición fluida.
Apel se une a Arrowhead desde Walgreens Boots Alliance, donde fue Jefe Global de Planificación y Análisis Financiero (2019-2024). Su amplia experiencia incluye casi 20 años en Bayer, donde ocupó cargos como Director Financiero de Bayer U.S. (2016-2019) y Director Financiero de Bayer Canadá. La transición ocurre mientras Arrowhead se prepara para el lanzamiento previsto de plozasiran este año, sujeto a la aprobación regulatoria, marcando el paso de la compañía de la etapa de desarrollo a la comercial.
Arrowhead Pharmaceuticals (NASDAQ: ARWR)는 주요 리더십 변화를 발표하며, 2025년 5월 13일부로 다니엘 아펠(Daniel Apel)을 새로운 최고재무책임자(CFO)로 임명했습니다. 그는 16년간 회사에 재직한 켄 미스코프스키(Ken Myszkowski)를 이어 받습니다. 미스코프스키는 원활한 인수인계를 위해 고문으로 남을 예정입니다.
아펠은 Walgreens Boots Alliance에서 글로벌 재무 기획 및 분석 책임자(2019-2024)를 역임했으며, 바이엘에서 거의 20년간 근무하며 미국 바이엘 CFO(2016-2019)와 캐나다 바이엘 CFO를 맡은 폭넓은 경력을 가지고 있습니다. 이번 인사는 Arrowhead가 규제 승인 대기 중인 플로자시란(plozasiran)의 올해 출시를 준비하는 시점에 이루어졌으며, 이는 회사가 개발 단계에서 상업 단계로 전환하는 것을 의미합니다.
Arrowhead Pharmaceuticals (NASDAQ : ARWR) a annoncé un changement clé dans sa direction, avec la nomination de Daniel Apel en tant que nouveau Directeur Financier, à compter du 13 mai 2025. Il succède à Ken Myszkowski, qui prend sa retraite après 16 ans au sein de l’entreprise. Myszkowski restera conseiller interne pour assurer une transition en douceur.
Apel rejoint Arrowhead après avoir occupé le poste de Global Head of Financial Planning and Analysis chez Walgreens Boots Alliance (2019-2024). Son expérience approfondie inclut près de 20 ans chez Bayer, où il a été CFO de Bayer U.S. (2016-2019) et CFO de Bayer Canada. Cette transition intervient alors qu’Arrowhead se prépare au lancement prévu de plozasiran cette année, sous réserve d’approbation réglementaire, marquant le passage de l’entreprise de la phase de développement à la phase commerciale.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) gab eine wichtige Führungsänderung bekannt: Daniel Apel wird ab dem 13. Mai 2025 neuer Chief Financial Officer. Er folgt auf Ken Myszkowski, der nach 16 Jahren im Unternehmen in den Ruhestand geht. Myszkowski bleibt als Berater im Unternehmen, um einen reibungslosen Übergang zu gewährleisten.
Apel kommt von Walgreens Boots Alliance, wo er von 2019 bis 2024 als Global Head of Financial Planning and Analysis tätig war. Seine umfangreiche Erfahrung umfasst fast 20 Jahre bei Bayer, wo er als CFO von Bayer U.S. (2016-2019) und CFO von Bayer Canada tätig war. Der Wechsel erfolgt, während Arrowhead sich auf die geplante Markteinführung von Plozasiran in diesem Jahr vorbereitet, vorbehaltlich der behördlichen Zulassung, was den Übergang des Unternehmens von der Entwicklungs- zur kommerziellen Phase markiert.
- Planned commercial launch of plozasiran in 2025 marks transition from development to commercial stage
- New CFO brings extensive pharmaceutical industry experience from Walgreens and Bayer
- Company maintains financial strength during transition period
- Structured transition plan with retiring CFO staying as adviser
- Loss of 16-year veteran CFO could impact institutional knowledge and continuity
“Ken has been a valuable member of the Arrowhead team, and he retires at a time of great financial strength for the company. The finance organization that Ken built over the years is very capable and provides strong support to our ambitious development and commercialization plans. I want to thank him for all his important contributions to Arrowhead,” said Christopher Anzalone, Ph.D., President and CEO at Arrowhead. “I am also excited for Dan Apel to join Arrowhead as we make the transition from development stage to commercial stage, with the planned launch of plozasiran this year, pending regulatory review and approval. Dan is an accomplished pharmaceutical executive who can make an immediate and important impact on our business.”
Mr. Apel joins the company from Walgreens Boots Alliance, where he served as Global Head of Financial Planning and Analysis from 2019 through 2024. Prior to joining Walgreens, Mr. Apel served in various significant roles in his nearly 20-year career at Bayer, including as Chief Financial Officer for Bayer
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.
For more information, please visit www.arrowheadpharma.com, or follow us on X (formerly Twitter) at @ArrowheadPharma, LinkedIn, Facebook, and Instagram. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.
Safe Harbor Statement under the Private Securities Litigation Reform Act:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “hope,” “intend,” “plan,” “project,” “could,” “estimate,” “continue,” “target,” “forecast” or “continue” or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future; our beliefs and expectations regarding milestone, royalty or other payments that could be due to or from third parties under existing agreements; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the impact of the ongoing COVID-19 pandemic on our business, the safety and efficacy of our product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.
Source: Arrowhead Pharmaceuticals, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250415506851/en/
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400
ir@arrowheadpharma.com
Investors:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578
britchie@lifesciadvisors.com
Media:
LifeSci Communications, LLC
Kendy Guarinoni, Ph.D.
724-910-9389
kguarinoni@lifescicomms.com
Source: Arrowhead Pharmaceuticals, Inc.
FAQ
When will Daniel Apel start as CFO of Arrowhead Pharmaceuticals (ARWR)?
What is the significance of the CFO transition for Arrowhead Pharmaceuticals (ARWR)?
What is Daniel Apel's professional background before joining ARWR?
When is Arrowhead Pharmaceuticals (ARWR) planning to launch plozasiran?
